Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Immunological properties of recombinant hepatitis B surface antigen expressed in mammalian cell (C127)


We examined the immunological properties of the recombinant hepatitis B surface antigen (r-HBsAg) which was expressed in mammalian cell (C127). The cross-immunity of r-HBsAg and plasma-derived hepatitis B surface antigen (p-HBsAg) were tested using Western blotting and ELISA with guinea pig polyclonal antibody and naturally infected human-derived antibody and the both antigens show the same results in their response pattern and intensity, which indicate they have a good cross-immunity. From the measurement of ED50 after formalin- or heat-inactivation, both r-HBsAg and p-HBsAg showed ED50 of 0.2∼0.3 in formalin-inactivation, while r-HBsAg was 0.05∼0.09 and p-HBsAg was 0.03∼0.07 in heat-inactivation, which means heat-inactivation method is 3∼4 times superior in immunogenicity. In the immunopersistency test performed in guinea pig for the period of 3 months with two different adjuvants, antibody titer was 34.2 with muramyl dipeptide adjuvant, which was 1.8 times greater than the antibody titer of 18.9 with AlPO4 adjuvant. The mutagenicity of r-HBsAg, examined by Ames test and micronucleus test, were all negative. In conclusion, r-HBsAg has the same cross-immunity with p-HBsAg, and heat-inactivation method and muramyl dipeptide adjuvant allow development of r-HBsAg vaccine with excellent immunogenicity.

This is a preview of subscription content, log in to check access.

References Cited

  1. Allison, A. C. and Byars, N. E., Adjuvant formulations and their mode of action.Semin. Immunology, 2, 369–374 (1990).

  2. Blumberg, B. S., Alter, H. J. and Visnich, S., A new antigen in leukemia sera.JAMA, 191, 541–546 (1965).

  3. Blumberg B. S., Sutnick, A. L. and London, W. T., Hepatitis and leukemia: their relation to Australia antigen.Bull. N. Y. Acad. Med., 44, 1566–1586 (1968).

  4. Chung, T. H., Prevention strategy for hepatitis B virus infection with HBsAg immunization in Korea.9th Biennial Scientific Meeting of Asian Pacific Association for the Study of Liver. Jan. 26–29 (1994).

  5. Dane, D. S., Cameron, C. H. and Briggs, M., Viruslike particles in serum of patients with Australia-antigen-associated hepatitis.Lancet, 1, 695–698 (1970).

  6. Hilleman, M. R., Buynak, E. B., Roehm, R. R., Tytell, A. A., Bertland, A. U. and Lampson, G. P., Purified and inactivated human hepatitis B vaccine: progress report.Am. J. Med. Sci., 270, 401–404 (1975).

  7. Krone, B., Gerlich, W. H., Heermann, K. H., Lenz, A., Lu, X., Seiter, M. and Tomslen, R., Significance of pre-antigens for hepatitis B vaccines.Progress in hepatitis B immunization., 194, 21–33 (1990).

  8. Krugman, S., Giles, J. P. and Hammond, J., Hepatitis virus: effect of heat on the infectivity and antigenicity of the MS-1 and MS-2 strains.J. Infect. Dis., 122, 432–436 (1970).

  9. Krugman, S. and Giles, J. P., Viral hepatitis, type B (MS-2-strain). Further observations on natural history and prevention.N. Engl. J. Med., 288, 755–760 (1973).

  10. Lee, S. O., Soh, J. M., Park, B. H. and Min, B. K., Heat aggregated hepatitis B surface antigen and its effect on immune response.Korean J. Immunol., 9, 233 (1987).

  11. Michel, M. L., Sobczak, E., Malpiece, Y., Tiollais, P. and Streeck, R. E., Expression of amplified hepatitis B virus surface antigen genes in chinese hamster ovary cells.Biotechnology, 3, 561–566 (1985).

  12. Michel, M. L., Pontisso, P., Sobczak, E., Malpiece, Y., Streek, R. E. and Tiollais, P., Synthesis in animal all of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin.Proc. Natl. Acad. Sci. USA., 81, 7708–7712 (1984).

  13. Neurath, A. R., Antibodies to a synthetic peptide from the pre-S 120–145 region of the hepatitis B virus envelope are virus neutralizing.Vaccine, 4, 35–37 (1986).

  14. Przewlocki, G., Audibert, F., Jolivet, M., Chedid, L., Kent, S. B. H. and Neurath, A. R., Production of antibodies recognizing a hepatitis B virus (HBV) surface antigen by administration of murabutide associated to a synthetic pre-S HBV peptide conjugated to a toxoid career.Biochem. Biophys. Res. Comm., 140, 557–564 (1986).

  15. Purcell, R. H. and Gerin, J. L., Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees.Am. J. Med. Sci., 270, 395–399 (1975).

  16. Reesink, H. W., Reerink-Brongers, E. E., Brummelhuis, H. G. J. and Lafeberschut, L. J. P., Heat-inactivated HBsAg as a vaccine against hepatitis B.Antiviral Res., 1, 13 (1981).

  17. Rothman, A. L., Kurane, I., Mason, P. W., Innis, B. L. and Ennis, F. A., Dengue virus specific murine T response to recombinant viral proteins.J. Virol., 63, 2486–2491 (1989).

  18. Samanta, H. and Youn, B. W., Expression of hepatitis B virus surface antigen containing the Pre-S region in mammalian cell culture system.Vaccine, 7, 69–76 (1989).

  19. Tiollais, P., Charnay, P. and Vyas, G. N., Biology of hepatitis B virus.Science, 213, 406–411 (1981).

  20. Valenzuela, P., Medina, A., Rutter, W. J., Ammerer, G. and Hall, B. D., Synthesis and assembly of hepatitis B virus surface antigen particles in yeast.Nature, 298, 347–350 (1982).

Download references

Author information

Correspondence to Eung-Chil Choi.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lee, Y.S., Kim, B.K. & Choi, E. Immunological properties of recombinant hepatitis B surface antigen expressed in mammalian cell (C127). Arch. Pharm. Res. 21, 543–548 (1998). https://doi.org/10.1007/BF02975372

Download citation

Key words

  • Recombinant hepatitis B surface antigen (r-HBsAg)
  • Immunological properties
  • Plasma-derived hepatitis B surface antigen (p-HBsAg)
  • Cross immunity
  • Heat inactivation